CSPC PHARMACEUTICAL GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.25 HKD | +0.48% |
|
-0.95% | -13.91% |
| Sales 2024 * | 37.87B 4.85B | Sales 2025 * | 40.97B 5.24B | Capitalization | 73.8B 9.45B |
|---|---|---|---|---|---|
| Net income 2024 * | 7.15B 915M | Net income 2025 * | 7.68B 983M | EV / Sales 2024 * | 1.52 x |
| Net cash position 2024 * | 16.22B 2.08B | Net cash position 2025 * | 20.89B 2.67B | EV / Sales 2025 * | 1.29 x |
| P/E ratio 2024 * |
10.4
x | P/E ratio 2025 * |
9.7
x | Employees | 23,500 |
| Yield 2024 * |
3.39% | Yield 2025 * |
3.52% | Free-Float | 70.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.48% | ||
| 1 week | -0.95% | ||
| Current month | +0.48% | ||
| 1 month | -5.73% | ||
| 3 months | +1.63% | ||
| 6 months | -13.91% | ||
| Current year | -13.91% |
1 week
6.12
6.61
1 month
6.127.08
Current year
5.567.37
1 year
5.207.41
3 years
5.2011.90
5 years
5.2012.68
10 years
2.7713.93
| Managers | Title | Age | Since |
|---|---|---|---|
Cui Long Zhang
CEO | Chief Executive Officer | 55 | 95-12-31 |
Dong Chen Cai
CHM | Chairman | 70 | 97-12-31 |
Hao Jiang
BRD | Director/Board Member | 41 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 70 | 97-12-31 |
Huai Yu Wang
BRD | Director/Board Member | 61 | 09-12-31 |
Cheuk Kin Law
BRD | Director/Board Member | 61 | 21-03-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.05% | 1 M€ | -23.91% | - | |
| 2.02% | 4 M€ | -27.92% | ||
| 1.07% | 2 M€ | -1.78% | - | |
| 0.99% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 6.25 | +0.48% | 39,376,740 |
| 24-06-28 | 6.22 | -1.74% | 47,683,120 |
| 24-06-27 | 6.33 | -3.36% | 38,930,900 |
| 24-06-26 | 6.55 | +3.15% | 66,162,360 |
| 24-06-25 | 6.35 | +0.63% | 34,732,030 |
Delayed Quote Hong Kong S.E., July 02, 2024 at 04:08 am EDT
More quotes
CSPC Pharmaceutical Group Ltd. specializes in the development, manufacture and marketing of pharmaceutical products. Net sames by category of products break down as follows:
- drugs (78.7%): innovative drugs (62.5% of sales) and common generic drugs (37.5%);
- vitamin C (10.1%);
- antibiotics (6.2%);
- other (5%): including anhydrous and raw caffeine.
Net sales are distributed geographically as follows: China (82.8%), Asia (7.2%), Europe (4.6%), the Americas (4.4%) and others (1%).
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
6.25
HKD
Average target price
9.584
HKD
Spread / Average Target
+53.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.91% | 9.4B | |
| +55.55% | 823B | |
| +42.31% | 641B | |
| -6.83% | 352B | |
| +17.15% | 324B | |
| +7.09% | 301B | |
| +14.02% | 241B | |
| +1.64% | 223B | |
| +13.66% | 218B | |
| +7.87% | 167B |
- Stock Market
- Equities
- 1093 Stock
